MX2015011178A - Solucicones intratecales de hidromorfona con estabilidad mejorada. - Google Patents

Solucicones intratecales de hidromorfona con estabilidad mejorada.

Info

Publication number
MX2015011178A
MX2015011178A MX2015011178A MX2015011178A MX2015011178A MX 2015011178 A MX2015011178 A MX 2015011178A MX 2015011178 A MX2015011178 A MX 2015011178A MX 2015011178 A MX2015011178 A MX 2015011178A MX 2015011178 A MX2015011178 A MX 2015011178A
Authority
MX
Mexico
Prior art keywords
improved stability
hydromorphone solutions
intrathecal
intrathecal hydromorphone
pharmaceutically acceptable
Prior art date
Application number
MX2015011178A
Other languages
English (en)
Inventor
John J Foster
Thomas R Prentice
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of MX2015011178A publication Critical patent/MX2015011178A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

En líneas generales, la presente descripción hace referencia a una solución farmacéutica que comprende hidromorfona o una sal farmacéuticamente aceptable de esta que se encuentra sustancialmente libre de soluciones amortiguadoras y opcionalmente, uno o más aditivos adicionales. La sal farmacéuticamente aceptable puede ser clorhidrato de hidromorfona. También se describen métodos para la elaboración y el uso de la solución.
MX2015011178A 2013-03-06 2013-09-06 Solucicones intratecales de hidromorfona con estabilidad mejorada. MX2015011178A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/787,042 US9155734B2 (en) 2012-03-07 2013-03-06 Stability of hydromorphone hydrochloride solutions
PCT/US2013/058519 WO2014137385A1 (en) 2013-03-06 2013-09-06 Intrathecal hydromorphone solutions having improved stability

Publications (1)

Publication Number Publication Date
MX2015011178A true MX2015011178A (es) 2015-11-30

Family

ID=49231622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011178A MX2015011178A (es) 2013-03-06 2013-09-06 Solucicones intratecales de hidromorfona con estabilidad mejorada.

Country Status (10)

Country Link
US (3) US9155734B2 (es)
EP (1) EP2964188A1 (es)
JP (1) JP6190475B2 (es)
KR (1) KR101892797B1 (es)
CN (1) CN105073095A (es)
BR (1) BR112015021480A2 (es)
CA (1) CA2902823C (es)
IL (1) IL240910B (es)
MX (1) MX2015011178A (es)
WO (1) WO2014137385A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2884406B1 (fr) 2005-04-14 2008-10-17 Memometal Technologies Soc Par Dispositif d'osteosynthese intramedullaire de deux parties d'os, notamment de la main et/ou du pied
FR2935601B1 (fr) 2008-09-09 2010-10-01 Memometal Technologies Implant intramedullaire resorbable entre deux os ou deux fragments osseux
US9155734B2 (en) 2012-03-07 2015-10-13 Mallinckrodt Llc Stability of hydromorphone hydrochloride solutions
CN107028968B (zh) * 2016-02-03 2020-12-04 江苏恒瑞医药股份有限公司 一种含有葡萄糖醛酸吗啡或其可药用盐的药物组合物
US10470807B2 (en) 2016-06-03 2019-11-12 Stryker European Holdings I, Llc Intramedullary implant and method of use
US12011440B2 (en) 2022-03-23 2024-06-18 Hikma Pharmaceuticals Usa Inc. Ready-to-administer hydromorphone formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011681A1 (en) 1995-09-29 1997-04-03 Lam Pharmaceuticals Inc. Sustained release delivery system and long acting narcotic analgesics and antagonists
EP2003134B1 (en) 1999-11-09 2011-03-02 Abbott Laboratories Hydromorphinone compositions
AU2003217436A1 (en) 2002-02-15 2003-09-09 Howard Brooks-Korn Use of opioid compound to treat a neurologic or neurogenic disorder
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
WO2005032556A1 (en) 2003-10-02 2005-04-14 Elan Pharmaceuticals, Inc. Method for reducing pain
WO2006113696A1 (en) * 2005-04-18 2006-10-26 Noramaco Inc. Hydromorphone polymorphs
BRPI0503734A (pt) * 2005-08-23 2007-04-27 Cristalia Prod Quimicos Farm composição farmacêutica na forma de solução injetável de morfina pronta para uso e forma de dosagem unitária de morfina para administração epidural ou intratecal
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
EP2341899B1 (en) * 2008-09-24 2014-12-17 Evonik Röhm GmbH Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
JP5619780B2 (ja) 2009-02-26 2014-11-05 テイコク ファーマ ユーエスエー インコーポレーテッド 癌性疼痛の治療のための麻薬性エマルション製剤
US9458536B2 (en) 2009-07-02 2016-10-04 Sio2 Medical Products, Inc. PECVD coating methods for capped syringes, cartridges and other articles
US8461171B2 (en) 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
ES2444591T3 (es) 2010-10-28 2014-02-25 Acino Pharma Ag Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada
CA2819635A1 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
WO2013063289A1 (en) 2011-10-25 2013-05-02 Lycus Llc Pharmaceutical compositions for treating pain
EP2776603B1 (en) 2011-11-11 2019-03-06 SiO2 Medical Products, Inc. PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS
US9155734B2 (en) 2012-03-07 2015-10-13 Mallinckrodt Llc Stability of hydromorphone hydrochloride solutions
EP2822535A1 (en) * 2012-03-07 2015-01-14 Mallinckrodt LLC Improved stability of hydromorphone hydrochloride solutions

Also Published As

Publication number Publication date
JP6190475B2 (ja) 2017-08-30
US20150359790A1 (en) 2015-12-17
IL240910B (en) 2019-08-29
KR101892797B1 (ko) 2018-08-28
IL240910A0 (en) 2015-10-29
JP2016510739A (ja) 2016-04-11
CN105073095A (zh) 2015-11-18
WO2014137385A1 (en) 2014-09-12
US9155734B2 (en) 2015-10-13
KR20150123804A (ko) 2015-11-04
EP2964188A1 (en) 2016-01-13
CA2902823C (en) 2019-06-11
CA2902823A1 (en) 2014-09-12
US20130237558A1 (en) 2013-09-12
BR112015021480A2 (pt) 2017-07-18
US20140005219A1 (en) 2014-01-02
US10905685B2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
PH12016502398A1 (en) Dihydropyrimido loop derivative as hbv inhibitor
PH12015501843A1 (en) Novel pyrazol derivatives
PT3027186T (pt) Processo para a preparação de composições compreendendo ácido hialurónico e cloridrato de mepivacaína
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2015011178A (es) Solucicones intratecales de hidromorfona con estabilidad mejorada.
UA116239C2 (uk) Нові похідні піридину
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
UA115357C2 (uk) Похідні піридин-4-ілу
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
WO2014153495A3 (en) Novel stat3 inhibitors
UA116654C2 (uk) Похідні пурину як агоністи канабіноїдного рецептора св2
IN2013CH05441A (es)
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
HK1220444A1 (zh) 拉喹莫德鈉晶體和用於製造它們的改進方法
IN2013MU01111A (es)
WO2014160177A3 (en) Quinazoline inhibitors of pi3k
IN2013MU04056A (es)
IN2013MU03565A (es)
IN2014DE01203A (es)
MX2016000775A (es) Preparacion farmaceutica que comprende un derivado de aminopirazol.
MX2016000797A (es) Imidazolcarboxamidas y su uso como inhibidores de amida de acidos grasos hidrolasa (faah).
IL241491A0 (en) Pharmaceutically acceptable amine salts of patvastatin
MX361779B (es) Estabilidad mejorada de soluciones de clorhidrato de hidromorfona.
MX2016002186A (es) Proceso para preparar dronedarona y sales de la misma.
UA117655C2 (uk) Спосіб синтезу 3-(2-бромо-4,5-диметоксифеніл)пропаннітрілу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою